Role of peripheral blood CD4+CD25high Treg percentage in the prognosis of ALL

doi:10.3969/j.issn.1673-8640.2019.04.008

Abstract

Abstract:

Objective To investigate the percentage changes of peripheral blood CD4⁺CD25^high regulatory T cells（Treg） in patients with acute lymphoblastic leukemia（ALL） before and after treatment. Methods Flow cytometry was used to determine CD4⁺CD25^high Treg percentage in peripheral blood of 22 ALL patients before and after treatment [vincristine,daunorubicin,cyclophosphamide and prednisone（VDCP）]. After 5-year follow-up,13 cases achieved complete remission（CR）（CR group）,and 9 cases of non-remission（NR）（NR group） were enrolled. Totally,20 healthy subjects were enrolled as healthy control group. Results Compared with healthy control group,the percentage of CD4⁺CD25^high Treg in peripheral blood increased before and after treatment in ALL group（P<0.05）. The percentage of CD4⁺CD25^high Treg in CR group was increased（P<0.001）,while NR group had no statistical significance before treatment（P>0.05）. The percentage of CD4⁺CD25^high Treg after treatment was slightly lower in ALL group than that before treatment without statistical significance（P>0.05）. The percentage of CD4⁺CD25^high Treg after treatment was lower in CR group than that before treatment（P<0.01）,and it was close to that in healthy control group（P>0.05）. The percentage of CD4⁺CD25^high Treg after treatment in NR group was higher than that before treatment（P<0.01）,and it was higher than that in healthy control group（P<0.001）. Conclusions CD4⁺CD25^high Treg in peripheral blood may be used as an indicator for the treatment efficiency of ALL.

Key words: Regulatory T cell, Flow cytometry, Acute lymphoblastic leukemia, Prognosis

CLC Number:

R446.1

ZHAO Lian, HE Jinlong, WU Cuiyun, ZHOU Haiyan, ZHOU Weilun, WU Cuiping. Role of peripheral blood CD4⁺CD25^highTreg percentage in the prognosis of ALL[J]. Laboratory Medicine, 2019, 34(4): 327-330.

Figures/Tables 1

References 16

[1]	APOSTOLOU I,VON BOEHMER H.In vivo instruction of suppressor commitment in naive T cells[J]. J Exp Med,2004,199(10):1401-1408.
[2]	巫翠萍,覃西,巫翠云,等.急性淋巴细胞白血病患者CD4+CD25+T调节细胞水平与白细胞介素2,白细胞介素10,转化生长因子β的检测[J].中国组织工程研究,2012,16(14):2648-2651.
[3]	张之南. 血液病诊断及疗效标准[M]. 天津:天津科学技术出版社,1991:106.
[4]	徐翀,关明,将黎敏,等. CD4+Foxp3+调节性T淋巴细胞在儿童急性白血病中的表达及其与微小残留病的关系[J]. 中华检验医学杂志,2009,32(3):321-325.
[5]	陆春伟,佟海侠,陆美言. 肿瘤患者外周血调节性T细胞的检测及临床意义[J]. 现代肿瘤医学,2011,19(7):1414-1416.
[6]	FONTENOT J D,RASMUSSEN J P,GAVIN M A,et al.A function for interleukin 2 in Foxp3-expressing regulatory T cells[J]. Nat Immunol,2005,6(11):1142-1151.
[7]	BAECHER-ALLAN C,BROWN J A,FREEMAN G J,et al.CD4+CD25high regulatory cells in human peripheral blood[J]. J Immunol,2001,167(3):1245-1253.
[8]	巫翠萍,覃西,王华民,等. 慢性乙型肝炎患者外周血CD4+CD25+Treg与CD4+CD8+T细胞亚群的相关研究[J]. 中国免疫学杂志,2010,26(3):273-277.
[9]	GONZALEZ-GAY M A,DE MATIAS J M,GONZALEZ-JUANATEY C,et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis[J]. Clin Exp Rheumatol,2006,24(1):83-86.
[10]	吴丕六. 小儿白血病病因学研究进展[J]. 医学信息,2015,28(43):451.
[11]	KONO K,KAWAIDA H,TAKAHASHI A,et al.CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers[J]. Cancer Immunol Immunother,2006,55(9): 1064-1071.
[12]	CESANA G C,DERAFFELE G,COHEN S,et al.Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma[J]. J Clin Oncol,2006,24(7):1169-1177.
[13]	BEYER M,KOCHANEK M,DARABI K,et al.Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine[J]. Blood,2005,106(6): 2018-2025.
[14]	CARRERAS J,LOPEZ-GUILLERMO A,FOX B C,et al.High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma[J]. Blood,2006,108(9):2957-2964.
[15]	ALVARO T,LEJEUNE M,SALVADÓ M T,et al.Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells[J]. Clin Cancer Res,2005,11(4):1467-1473.
[16]	GHIRINGHELLI F,MENARD C,PUIG P E,et al.Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients[J]. Cancer Immunol Immunother,2007,56(5): 641-648.

组别	例数	CD4⁺CD25^highTreg
正常对照组	20	3.83（3.43~4.54）
ALL组
治疗前	22	5.49（4.18~6.46）^**
治疗后	22	4.69（3.92~5.97）^*
CR组
治疗前	13	5.67（4.82~6.49）^**
治疗后	13	3.98（3.74~4.70）^#
NR组
治疗前	9	4.23（3.30~6.84）
治疗后	9	5.70（4.96~8.55）^***#

组别	例数	CD4⁺CD25^highTreg
正常对照组	20	3.83（3.43~4.54）
ALL组
治疗前	22	5.49（4.18~6.46）^**
治疗后	22	4.69（3.92~5.97）^*
CR组
治疗前	13	5.67（4.82~6.49）^**
治疗后	13	3.98（3.74~4.70）^#
NR组
治疗前	9	4.23（3.30~6.84）
治疗后	9	5.70（4.96~8.55）^***#